Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study

Peter C. Thuss-Patience, Manish A. Shah, Atsushi Ohtsu, Eric Van Cutsem, Jaffer A. Ajani, Hugo Castro, Wasat Mansoor, Hyun Cheol Chung, Gyorgy Bodoky, Kohei Shitara, Gail D.Lewis Phillips, Tina van der Horst, Marie Laurence Harle-Yge, Betsy L. Althaus, Yoon Koo Kang

Research output: Contribution to journalArticle

140 Citations (Scopus)

Fingerprint Dive into the research topics of 'Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study'. Together they form a unique fingerprint.

Medicine & Life Sciences